Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges

Abstract excerpt

Abstract: MET exon 14 skipping mutation ( MET ∆ex14) is present about 3% of non-small cell lung cancers (NSCLCs). NSCLC patients with MET ∆ex14 are characterized by an average age of over 70 years at diagnosis, a smoking history and a higher frequency in pleomorphic carcinoma and adenosquamous cell carcinoma than in adenocarcinoma. It has also been reported that NSCLCs with MET ∆ex14 often have codriver...

Topics

Join the communities discussing this publication.

• Cholangiocarcinoma and Gallbladder Cancer Studies
• Hepatocellular Carcinoma Treatment and Prognosis
• Lung Cancer Treatments and Mutations